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Natural gene therapy in dystrophic 
epidermolysis bullosa



























background Dystrophic epidermolysis bullosa is a genetic blistering disorder caused by 
mutations in the type VII collagen gene, COL7A1. In revertant mosaicism, germline muta-
tions are corrected by somatic events resulting in a mosaic disease distribution. This ‘natu-
ral gene therapy’ phenomenon has long been recognized in other forms of epidermolysis 
bullosa but only recently in dystrophic epidermolysis bullosa. 
observations We describe a 21-year-old man with recessive dystrophic epidermolysis bul-
losa carrying the homozygous c.6508C>T (p.Gln2170X) nonsense mutation who reported 
an unaffected skin patch on his neck where blisters never had occurred. Immunofluores-
cent type VII collagen staining was normal in 80% of the unaffected skin biopsy; however, 
it was strongly reduced in the affected skin. In the unaffected skin, the somatic nucleotide 
substitution c.6510G>T reverted the germline nonsense codon to tyrosine (p.Gln2170Tyr), 
thereby restoring functional protein production.
Conclusions Revertant mosaicism is considered rare in recessive dystrophic epidermolysis 
bullosa. However, it might be more common than previously anticipated because our 
patient is the third patient in whom revertant mosaicism was identified in a short time. The 
correction mechanism is different than that previously reported. Systematic examination 
of patients with recessive dystrophic epidermolysis bullosa, therefore, will likely reveal 
more patients with revertant patches. This is important because the natural gene therapy 
phenomenon may provide opportunities for revertant cell therapy.
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iNTroDuCTioN
Revertant mosaicism is the phenomenon in which the pathogenic effect of a germline muta-
tion in a specific gene is corrected by a second, somatic event, thus giving rise to a mosaic 
appearance of mutant and revertant tissue.1 This ‘natural gene therapy’ phenomenon has been 
described for several genetic disorders, among which the heritable blistering disorder epider-
molysis bullosa (EB), especially the non-Herlitz junctional subtypes.2-5 In fact, over one third 
of non-Herlitz JEB patients with either LAMB3 or COL17A1 mutations displayed revertant skin 
patches.6 As recently summarized by Lai-Cheong et al., several different correction mechanisms 
have been uncovered, such as back mutations, additional nucleotide changes, insertions or 
deletions, and gene conversions,5 sometimes even within the same patient.6-8 Revertant mosa-
icism also has been described for patients with EB simplex who have KRT14 mutations and for 
a patient with Kindler syndrome.9-11 However, revertant mosaicism in dystrophic epidermolysis 
bullosa (DEB) had not been recognized until recently. Almaani et al. identified the first patient 
known to have recessive DEB (RDEB) with revertant mosaicism due to an intragenic crossover 
within the type VII collagen (COLVII) gene, COL7A1.12 Pasmooij et al. subsequently reported 
on revertant mosaicism in a patient with RDEB due to a somatic nucleotide deletion within 
COL7A1.13 Herein, we describe a patient with RDEB who has revertant mosaicism due to a third 
type of correction, a nucleotide substitution that corrects the germline nonsense codon by 
changing it to a tyrosine.
rePorT of A CAse
The patient (identification No. EB024) was first seen in our clinic at the age of 6 years, when 
he was diagnosed as having the generalized other subtype of RDEB,14 after which the family 
discontinued follow-up in our clinic. At the age of 21 years, he re-contacted our clinic with gen-
eralized blistering, scarring, and atrophic skin. He had developed moderate flexion contractures 
of the fingers and partial fusion of the fingers and toes; therefore, he was diagnosed as having 
generalized other RDEB with late-onset pseudosyndactyly (he is also patient 17 in the study by 
Van den Akker et al.15). After being asked explicitly, he reported a skin patch in his neck where, 
in contrast to the rest of his body, blisters had never developed spontaneously, not even after 
scratching. The patch had been present as long as he could remember and it had not grown. 
On examination, a pale skin patch of approximately 2.5 x 3.0 cm on the right lateral portion of 
his neck stood out from the surrounding erythematous skin that had EB (Figure 1A). This patch 
resembled unaffected skin. Small hairs and hair follicles were visible in this patch (Figure 1B).
After ethical approval by the Institutional Review Board of the University Medical Center 
Groningen and informed consent (in accordance with the tenets of the Declaration of Helsinki), 
4-mm punch biopsy samples were collected from a nonlesional area of affected skin from the 
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left upper leg and from the unaffected skin patch of the neck. Immunofluorescence analysis 
with monoclonal antibodies LH7:2 (Sigma-Aldrich CoLLC, St Louis, Missouri) and 2Q633 (United 
States Biological, Swampscott, Massachusetts) showed strongly reduced staining of COLVII (Fig-
ure 1C) in the biopsy sample from nonlesional affected skin, representing mutant DEB skin. The 
biopsy sample from unaffected skin revealed COLVII staining with the same intensity as normal 
human control skin over 80% of the dermal-epidermal junction (Figure 1D and E), representing 
revertant keratinocytes. The other 20% of the dermal-epidermal junction displayed strongly 
reduced COLVII staining, comparable with that of mutant skin. Anchoring fibrils, as visualized 
by electron microscopy, were absent in mutant skin (data not shown).15 A biopsy sample from 
the revertant skin patch to be examined by electron microscopy could not be obtained.
Mutation analysis of COL7A1 in genomic DNA from peripheral leukocytes revealed a homozy-
gous C>T transition at nucleotide position 6508 in exon 80 (c.6508C>T) (GenBank NM_000094.3, 
OMIM 120120).15 This transition introduces a premature termination codon (PTC) at codon 
2170 (p.Gln2170X). The breakdown of messenger RNA molecules harboring this PTC following 
the nonsense-mediated messenger RNA decay pathway explains the strongly reduced COLVII 
staining in mutant skin.16 We performed laser dissection microscopy using the Leica LMD6000 
laser micro-dissection microscope (Leica Microsystems GmbH, Wetzlar, Germany) on 4-mm skin 
cryosections from mutant and revertant skin to separate keratinocytes with normal COLVII 
staining from those with reduced staining and from fibroblasts.13 Also, RNA was isolated from 
5-mm sections of mutant and revertant skin (Qiagen RNeasy Plus Micro Kit, Qiagen NV, Venlo, 
figure 1. Revertant skin patch and restoration of type VII collagen staining. The pale revertant skin patch 
stands out against erythematous skin (A). Note the follicular skin texture (b). Immunofluorescent type VII 
collagen staining is strongly reduced along the dermal-epidermal junction in affected skin (C), but normal 
in the revertant skin (D), compared to normal control skin (e). Scale bars: 50 mm.
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the Netherlands), and complementary DNA (cDNA) was synthesized as described.13 Subse-
quently, nested polymerase chain reaction assays were performed on genomic DNA and cDNA 
(for primers, see the study of Pasmooij et al.13). As expected, mutant keratinocytes carried the 
homozygous c.6508C>T transition (Figure 2A). However, in addition to this germline mutation, 
mutation analysis of revertant keratinocytes disclosed the extra heterozygous transversion 
c.6510G>T that was not present in keratinocytes from mutant skin or in fibroblasts from either 
type of skin. This somatic mutation is located 2 nucleotides downstream from the germline 
c.6508C>T mutation and corrects the PTC at codon 2170 on 1 allele by changing it to tyrosine 
(Figure 2B). Hence, in his revertant skin patch, our patient is functionally homozygous for the 
missense change p.Gln2170Tyr. The c.6510G>T reversion mutation also was present in cDNA of 


























GGT  CTG  CAG  GGT  CCA  AGA
Gly     Leu    Gln     Gly     Pro     Arg
GGT  CTG  TAG  GGT  CCA  AGA
Gly     Leu    Ter     Gly     Pro     Arg
GGT  CTG  TAT   GGT  CCA  AGA




figure 2. Correction of the germline mutation in revertant keratinocytes. A. On scale representation of 
genomic area around COL7A1 exon 80. The c.6508C>T transition is present homozygously in mutant 
keratinocytes. An additional heterozygous c.6510G>T transversion resides in the germline mutated codon 
in revertant keratinocytes. b. This somatic mutation corrects the germline nonsense codon by changing it 




For many years, revertant mosaicism, also known as natural gene therapy, resulting from 
spontaneous somatic correction events was observed almost exclusively in the non-Herlitz 
junctional subtypes of EB.1,2,6-8 Although occasional case reports have appeared describing 
revertant mosaicism in patients with autosomal dominant EB simplex, autosomal recessive EB 
simplex, and Kindler syndrome,9-11 revertant mosaicism was not identified in DEB, which raised 
the question of whether it did not occur in DEB or whether it simply was not recognized in 
patients with DEB. With the recent identification of revertant mosaicism resulting from spon-
taneous somatic correcting events in COL7A1 in two patients with RDEB,12,13 it was shown that 
natural gene therapy does occur in all four major EB types, including DEB.
The identification of revertant mosaicism in the patient with RDEB described herein sug-
gests that somatic correction events are more common in COL7A1 than previously anticipated. 
It is probable that revertant skin has been overlooked in other patients with RDEB in the past 
because it was not recognized as such. To date, in the reports of patients with RDEB who have 
revertant mosaicism, the revertant skin patches stood out as pale areas surrounded by ery-
thematous eroded skin.12,13 Systematic examination of patients with RDEB for similar patches, 
therefore, will likely disclose revertant skin in more patients.
In future studies, the identification of additional patients with RDEB who have revertant 
mosaicism will reveal the absolute frequency of natural gene therapy occurring on COL7A1 
alleles. This will answer the question of whether somatic correction events of mutant alleles 
are as common in COL7A1 as in LAMB3 and COL17A1, which are found in more than one-third 
of Dutch patients with non-Herlitz junctional EB.6 Also, it will reveal more information regard-
ing the intriguing and as-yet-unsolved question of whether the LAMB3 and COL17A1 genes in 
keratinocytes are more prone to somatic mutations than are the other EB-associated genes.
The reasons that correction mutations are frequently observed in EB genes, including 
COL7A1, remain elusive. Also, it is unclear at what exact time point they occur. A role for UV 
exposure or other environmental factors can be hypothesized because UV has the potential to 
induce somatic DNA mutations.17 If such exogenous factors are the cause, the mechanism of 
revertant skin patch development would consist of postnatal correction mutation induction 
in one stem cell giving rise to an expanding patch of healthy skin because of positive selec-
tion. Although this mechanism might apply to some patients, it seems unlikely in our patient, 
because his revertant skin had maintained unchanged shape and size for as long as he could 
remember. Also, because it has been shown that epidermal stem cells populate only small skin 
areas by the formation of epidermal proliferative units,18 it seems more likely that the correc-
tion mutation arose in earlier stages of embryonic epidermal stem cell development. Whether 
the occurrence of correcting mutations is random or driven by genetic or nongenetic factors, 
as suggested for KRT10 frame-shift mutations causing ichthyosis with confetti,19 remains a topic 
for further research.
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The patient described herein displays a novel correction mechanism in the COL7A1 gene. 
Hence, different correcting mechanisms occur in COL7A1, as in COL17A1 and LAMB3,5 whereas 
in patients with ichthyosis with confetti due to dominant KRT10 mutations, the same correction 
mechanism of mitotic recombination occurs in each revertant skin spot in each patient.19 In our 
patient, a somatic nucleotide change in the germline mutated codon rescues the mutant phe-
notype by reverting the nonsense codon to a tyrosine (p.X2170Tyr), which leads to the restora-
tion of functional protein production. The resultant missense change p.Gln2170Tyr has been 
described neither as a neutral polymorphism (dbSNP, www.ncbi.nlm.nih.gov/projects/SNP/) 
nor as a pathogenic mutation in patients with RDEB (International Dystrophic Epidermolysis 
Bullosa Patient Registry, www.deb-central.org, accessed on June 30, 2011).20 This missense 
change resides at the third position of a Gly-X-Y triplet and, contrary to substitutions of glycine 
residues at the first position of the Gly-X-Y triples,21 it is difficult, if not impossible, to predict 
the effect of such amino acid substitutions on triple-helix stability and clinical outcome. The 
pathogenicity prediction software package AlaMut version 2.0 (Interactive Biosoftware, Rouen, 
France), classifies the p.Gln2170Tyr missense change as being of unknown pathogenicity. As 
indicated by the normal immunofluorescence staining and negative history of blistering in 
the revertant patch, the missense change does not seem to severely affect COLVII functioning. 
Altogether, it remains unknown whether the resultant p.Gln2170Tyr change affects triple-helix 
stability, but a mild pathogenic effect cannot be excluded. 
Identification of revertant skin patches in patients with RDEB is important because revertant 
skin can be regarded as that in which gene therapy has been performed successfully by nature 
itself. This finding renders promising therapeutical opportunities, such as revertant cell therapy, 
namely, grafting of ex vivo-grown reverted keratinocytes onto affected skin.22 Keratinocytes and 
fibroblasts can be reprogrammed into induced pluripotent stem cells (iPSCs) and subsequently 
differentiated into keratinocytes, providing an unlimited source of autologous keratinocytes.23 
Recently, two groups described the generation of iPSCs from the cells of patients with RDEB and 
the subsequent spontaneous24 and directed25 differentiation of these iPSCs into keratinocytes. 
The use of revertant cells obviates the need for potentially dangerous virus-mediated gene 
correction26 and circumvents the risk of immunological rejection, and, if combined with the 
patient-specific iPSCs approach, provides the opportunity to grow a large number of healthy 
skin grafts. Moreover, differentiation of revertant iPSCs into hematopoietic or mesenchymal 
stem cells would provide an autologous alternative for allogenic bone marrow stem cell trans-
plantation in this genetic disease.27,28 Altogether, revertant skin patches offer exciting future 
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